BESORFIB
Live / Allowed — Fourth extension granted (statement of use) (as of 01 Jun 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 22 Aug 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 98144113
- Mark type
- Word mark
- Filed
- 22 Aug 2023
- Published for opposition
- 28 May 2024
- Attorney of record
- Heather A. McDonald
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use
Owner
- Pfizer Inc., New York, NY, US
- Pfizer Inc., New York, NY, US
Prosecution history
- 02 Jun 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Jun 2026 — SOU EXTENSION 4 GRANTED
- 01 Jun 2026 — SOU EXTENSION 4 FILED
- 01 Jun 2026 — SOU TEAS EXTENSION RECEIVED
- 02 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Dec 2025 — SOU EXTENSION 3 GRANTED
- 01 Dec 2025 — SOU EXTENSION 3 FILED
- 01 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 May 2025 — SOU EXTENSION 2 GRANTED
- 30 May 2025 — SOU EXTENSION 2 FILED
- 30 May 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Nov 2024 — SOU EXTENSION 1 GRANTED
- 21 Nov 2024 — SOU EXTENSION 1 FILED